Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

6.8K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.8K
Blind Procedures02:07

Blind Procedures

12.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

523
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

449
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissociative symptom trajectories during treatment with selective serotonin reuptake inhibitors for depressive or anxiety disorders.

BMC psychiatry·2026
Same author

Digital-Supported Delivery of Behavioural Therapy for Patients with Tic Disorders: A Narrative Review.

Brain sciences·2026
Same author

Monogenic forms of Parkinson's disease: a Czech cohort study.

Neurologia i neurochirurgia polska·2026
Same author

High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder.

Movement disorders clinical practice·2026
Same author

Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review.

Pharmacy (Basel, Switzerland)·2026
Same author

The Prevalence of Tic Disorders in Poland: Regional and Sex Differences.

Tremor and other hyperkinetic movements (New York, N.Y.)·2026

Related Experiment Video

Updated: Jan 10, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.6K

Placebo in Functional Neurological Disorders: Promise and Controversy.

Natalia Szejko1,2,3,4, Ali Abusrair5, Tomasz Pasierski2

  • 1Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30-625 Hannover, Germany.

Healthcare (Basel, Switzerland)
|November 27, 2025
PubMed
Summary

Placebo, nocebo, and lessebo effects are common in neurological and psychiatric disorders. Their use in functional neurological disorders (FNDs) is debated due to ethical concerns, despite potential therapeutic benefits.

Keywords:
ethicsfunctional neurological disorderslessebo effectnocebo effectplacebo effect

More Related Videos

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety
10:51

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety

Published on: January 20, 2012

21.7K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

Related Experiment Videos

Last Updated: Jan 10, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.6K
Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety
10:51

Real-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety

Published on: January 20, 2012

21.7K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Ethics

Background:

  • Placebo, nocebo, and lessebo effects are prevalent in neurological and psychiatric conditions.
  • Neural mechanisms of placebo effects overlap with those targeted by active pharmaceutical interventions.
  • Functional neurological disorders (FNDs) involve shared neural substrates between the placebo network and dysfunctional pathways.

Purpose of the Study:

  • To discuss the application of placebo, nocebo, and lessebo in FNDs.
  • To explore the ethical implications of using these effects in FND management.
  • To examine the controversy surrounding placebo use in FND diagnosis and therapy.

Main Methods:

  • Literature review and ethical analysis.
  • Discussion of neural mechanisms and shared substrates.
  • Examination of ethical principles: informed consent, autonomy, nonmaleficence, beneficence, and justice.

Main Results:

  • Placebo effects share neural substrates with FND pathophysiology, particularly in emotion regulation, stress response, and self-agency.
  • The use of placebo in FNDs presents significant ethical challenges.
  • Placebo interventions in FNDs are considered controversial for both diagnostic and therapeutic purposes.

Conclusions:

  • While potentially safe and unique, placebo use in FNDs raises ethical concerns regarding core medical principles.
  • The application of placebo in FNDs challenges established doctor-patient relationships, particularly concerning autonomy and openness.
  • Further ethical deliberation is required for the responsible consideration of placebo interventions in FNDs.